Drug Profile
Balofloxacin
Alternative Names: Baloxin; Neuquinoron; Q 35; Q-RoxinLatest Information Update: 13 Jun 2011
Price :
$50
*
At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharmaceutical; JW Pharmaceutical; Novartis
- Class Antibacterials; Fluoroquinolones; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Bacterial infections
Most Recent Events
- 31 Oct 2002 Chugai Pharmaceutical has been acquired by Roche
- 14 Feb 2002 Registered for Bacterial infections in South Korea (PO)
- 06 Jul 1999 No-Development-Reported for Bacterial infections in South Korea (PO)